Senseonics (SENS), the continuous glucose monitoring company has been granted a new patent for their CGM device.
The patent was granted yesterday July 27 and details that the device could be used for measuring and monitoring other medical analyte concentrations.
This means that the device will be able to measure and monitor other medical analyte concentrations other than glucose levels, like triglycerides, blood glucose, and cholesterol.
This could open up the device for non-diabetic people who also want to monitor their cholesterol, triglycerides and glucose levels.
SENS upcoming earnings call
The company also announced that it plans to release its second quarter 2023 financial results after market close on Monday, August 9, 2023.
Management will hold a conference call to review the company’s second quarter 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day.
